Sign inCreate account

Report workspace tools

NCT02682693COMPLETEDanonymous

Investigating Denosumab as an add-on Neoadjuvant Treatment for RANK-positive or RANK-negative Primary Breast Cancer and Two Different Nab-Paclitaxel Schedules ; 2x2 Factorial Design (GeparX)

Sponsor

Source record

GBG Forschungs GmbH

Phase

Source record

Phase 2

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

RANK-positive or RANK-negative Primary Breast Cancer

Indication / condition

AI-normalized

Breast Cancer Female NOS

Intervention

Source record

Denosumab, nab-Paclitaxel, Epirubicin, Cyclophosphamide, Carboplatin, Trastuzumab, Pertuzumab

Source & freshness

Source record

NCT ID

NCT02682693

Original source

ClinicalTrials.gov

Source last updated

Feb 02, 2021

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02682693

Title

Investigating Denosumab as an add-on Neoadjuvant Treatment for RANK-positive or RANK-negative Primary Breast Cancer and Two Different Nab-Paclitaxel Schedules ; 2x2 Factorial Design (GeparX)

Sponsor

GBG Forschungs GmbH

Status

COMPLETED

Phase

Phase 2

Condition raw

Breast Cancer Female NOS

Condition normalized

Breast Cancer Female NOS

Modality raw

Breast Cancer Female NOS

Modality normalized

monoclonal antibody

Target raw

RANK-positive or RANK-negative Primary Breast Cancer

Target normalized

RANK-positive or RANK-negative Primary Breast Cancer

Interventions

Denosumab, nab-Paclitaxel, Epirubicin, Cyclophosphamide, Carboplatin, Trastuzumab, Pertuzumab

Public preview

Source record

The GeparX trial investigated denosumab as an adjunct to neoadjuvant chemotherapy in patients with RANK-positive breast cancer. Conducted by GBG Forschungs GmbH in collaboration with Amgen and Celgene, the study aimed to enhance pathological complete response (pCR) rates and improve patient outcomes. The trial enrolled 780 participants and was completed in December 2020.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Investigating Denosumab as an add-on Neoadjuvant Treatment for RANK-positive or RANK-negative Primary Breast Cancer and Two Different Nab-Paclitaxel Schedules ; 2x2 Factorial Design (GeparX)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02682693

Status

COMPLETED

Phase

Phase 2

Sponsor

GBG Forschungs GmbH

Executive brief

Investment-Ready Snapshot

The GeparX trial investigated denosumab as an adjunct to neoadjuvant chemotherapy in patients with RANK-positive breast cancer. Conducted by GBG Forschungs GmbH in collaboration with Amgen and Celgene, the study aimed to enhance pathological complete response (pCR) rates and improve patient outcomes. The trial enrolled 780 participants and was completed in December 2020.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedFeb 02, 2021
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02682693

Indication

Breast Cancer Female NOS

Modality

monoclonal antibody

Target

RANK-positive or RANK-negative Primary Breast Cancer

Intervention

Denosumab, nab-Paclitaxel, Epirubicin, Cyclophosphamide, Carboplatin, Trastuzumab, Pertuzumab

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.